Articles

Transiently achieved very low LDL-cholesterol levels by statin and alirocumab after acute coronary syndrome are associated with cardiovascular risk reduction: the ODYSSEY OUTCOMES trial

Schwartz GG, Szarek M, Bhatt DL, et al.

First published: March 5, 2023  DOI: 10.1093/eurheartj/ehad144